Sanofi SA Earnings - Q2 2026 Analysis & Highlights
Sanofi reports strong Q2 2026 performance with double-digit sales growth driven by Dupixent momentum and successful pharma launches, while management outlines comprehensive R&D transformation, strategic M&A acceleration, and China expansion under new CEO Belén Garijo López.
Key Financial Results
Q2 net sales grew 17.8% to €11.6 billion, primarily volume-driven with positive adjustments in gross-to-net deductions of a couple hundred million euros.
Gross margin increased by 3.7 percentage points, benefiting from reversal of inventory provisions following Sarclisa SubQ regulatory approval, with underlying gross margin improvement of approximately 1.7 percentage points driven by favorable product mix and efficiency.
Operating expenses increased by 13.1%, primarily driven by Blueprint and Dynavax acquisitions, but excluding acquisition impact, OpEx grew at a moderate single-digit rate.
Business operating income (BOI) increased by 35.8% with BOI margin expanding by 3.8 percentage points, driven by gross leverage, cost discipline, and favorable phasing of capital gains approximately €80 million higher than prior year quarter.
Business EPS grew strongly at 33.3%, with underlying business EPS growth reaching 21% excluding share buyback and one-off items.
H1 sales growth was 15.7% and business EPS was 22.7%, with underlying sales growth around 13%.
Business Segment Results
Pharma launches represented 13% of sales and grew over 60% in Q2, with ALTUVIIIO continuing strong momentum in hemophilia A as the top choice for patient switches in the US.
Ayvakit continues to expand in systemic mastocytosis, driven by continued growth in the number of patients treated and duration of treatment.
Sarclisa is performing well in multiple myeloma with recent subcutaneous regulatory approval providing greater convenience for patients.
Dupixent exceeded €5 billion in quarterly sales for the first time with more than 1.5 million patients currently under treatment globally, growing 37% in Q2 driven largely by volume.
Rare disease sales reached nearly €1.9 billion, up by 24%, driven by Ayvakit and ALTUVIIIO with most medicines across the franchise growing in volume.
Vaccine sales reached €1.15 billion in Q2, 5% lower than last year, reflecting high 2025 comparison base in influenza.
Beyfortus sales grew by 54% to €108 million, driven by a late US season and continued geographic expansion.
Heplisav-B grew by 43% on a pro forma basis to €113 million, offsetting expected impact of birth cohort dynamics of the pediatric franchise.
Established medicines were stable in the quarter.
Capital Allocation
Sanofi confirms commitment to dividend policy and capital allocation principles.
Share buyback benefits contributed to EPS growth, though reduced benefits from share buyback are expected in H2 2026.
BD and M&A investment of €47 billion over the last eight years resulted in €40 billion of value creation after €7 billion of losses.
Moderate increases in R&D spend expected in coming months, with R&D spend moving in parallel to any potential BD or M&A additions.
Industry Trends and Dynamics
Penetration of biologics across indications remains very low, reflecting significant opportunity for continued growth.
China represents an extraordinary source of innovation with speed and ecosystem being particularly interesting for pharmaceutical development.
US vaccination coverage rates have decreased, particularly for pediatric vaccines, impacting vaccine market dynamics.
Dupixent demand remains robust across indications and geographies with underlying demand higher than script data reflects.
Competitive Landscape
Dupixent remains the number one prescribed biologic across important prescriber groups in the US.
Sarclisa became the first anticancer medicine approved in the US, EU, and Japan to be given either subcutaneously or via an on-body injector.
Recent competitor data supports confidence in long-term potential of Amvuttra medicine.
Management acknowledges challenges in immunology pipeline but emphasizes that issues relate to operational rigor rather than immunology capabilities themselves.
Macroeconomic Environment
Foreign exchange headwinds impact 2030 guidance, with today's euro/dollar rate less favorable than rates used when ambitions were set in 2023.
US policy changes affecting vaccine market, with new US administration policies contributing to weaker vaccination coverage rates.
De-globalizing market dynamics requiring greater accountability and empowered country leadership.
Growth Opportunities and Strategies
Upgraded 2030 Dupixent ambition to approximately €25 billion in sales, reflecting continued strong momentum and growth across all indications.
Rare diseases identified as area with greater opportunity ahead given strong capabilities and market leadership position.
China expansion prioritized with Thomas Triomphe appointed to lead China operations, combining decision-making with speed and agility.
Sanofi Global Health Unit reaching 30 underserved countries with medicines available through impact, the non-for-profit brand of WHO essential medicines.
Comprehensive outside-in portfolio review launched to inform decisions on pipeline with focus on latest stage pipeline.
Strategic focus on scientific rigor and fact-based decision-making in R&D, particularly in phase 2 to phase 3 transitions.
Paulo Fontoura appointed as new Head of R&D starting September, described as scientifically rigorous with proven track record of leading large global organizations.
Regeneron alliance discussions ongoing and productive, with focus on identifying opportunities for further collaboration and rebuilding trust.
BD and M&A strategy evolving to include more late-stage and commercial assets in addition to early-stage assets.
Appetite for larger M&A deals as an option subject to opportunity feasibility and strategic fit, science quality, and financial guardrails.
Financial Guidance and Outlook
2026 sales growth guidance upgraded to approximately 10% at constant exchange rates with business EPS growing slightly faster than sales.
Vaccine sales growth expected to be slightly negative in 2026, mainly crystallizing in H2 due to usual seasonality.
Q3 specifically expects low- to mid-teens sales decrease, reflecting different distribution between Q3 and Q4 of respiratory vaccine sales compared to last year.
Full year 2026 tax rate anticipated at approximately 21%, reflecting non-deductibility of certain impairment losses on intangible assets linked to recent pipeline decisions.
Regeneron development balance reimbursement ends in Q2 2026, with Amvuttra royalties expected to fully offset this negative BOI impact for full year 2026.
2027 will see negative €200 million BOI gap between Regeneron reimbursement ending (€600 million negative impact) and Amvuttra royalties increasing (€400 million positive impact).
Pharmaceutical launches ambition remains unchanged at approximately €10 billion in sales by 2030, reflecting strengths and diversity of launch portfolio.
Vaccine business expected to reach approximately €9 billion in sales by 2030, with €1 billion reduction split equally between currency impact and market dynamics.
Dupixent growth rate anticipated to moderate in H2 2026 as newly launched indications annualize and comparables become tougher.
Fewer one-off benefits to gross margin expected in H2 2026, with no further Regeneron development balance reimbursement anticipated.
R&D Pipeline and Strategic Review
Phase 3 studies did not achieve expected outcomes including two Dupixent studies in lichen simplex chronicus, second venglustat study in Fabry disease, and riliprubart stopped early in refractory CIDP based on IDMC recommendation.
Amlitelimab showed sustained response in ESTUARY long-term study but company decided not to progress to regulatory submission as part of ongoing strategic assessment.
Nexviazyme met all study endpoints in infantile-onset Pompe disease with 94% of infants alive and free from invasive ventilation at week 52.
Venglustat received US priority review for type 3 Gaucher disease with target action date of November 25.
Efdoralprin alfa demonstrated superiority over standard of care in AATD emphysema with mean functional AAT trough levels more than 3 times higher than weekly plasma-derived AAT.
Dupixent received US label expansion in chronic spontaneous urticaria for children and Tzield received US label expansion in stage 3 type 1 diabetes.
Cenrifki received EU approval for secondary progressive multiple sclerosis in patients without relapses, addressing disability progression.
Approximately one new phase 1 start planned every two months, representing meaningful step-up in research productivity.
Multiple phase 3 readouts expected through 2027 and 2028 including frexalimab in relapsing and secondary progressive multiple sclerosis, riliprubart in CIDP, and Wayrilz in IgG4-related disease and warm autoimmune hemolytic anemia.
Pipeline review ongoing with potential for additional asset discontinuations based on scientific merit and risk assessment.
Regeneron Alliance
Litigation focuses on narrow issue concerning information sharing with focus of alliance on maximizing Dupixent opportunity.
No barriers related to Regeneron to moving forward on M&A at this time.
Discussions with Regeneron productive and frequent, with focus on delivering on business collectively as an alliance.
Alliance described as one of the most successful in the industry.
Potential improvements to collaboration structure under consideration to be more agile and bring more transparency to operations.
